Ogen(redirected from Ogen melons)
Pregnancy Category: X
Oral: As part of HRT in the treatment of vasomotor symptoms of menopause.Treatment of various estrogen deficiency states, including:
- Female hypogonadism,
- Primary ovarian failure.
Estrogens promote the growth and development of female sex organs and the maintenance of secondary sex characteristics in women.
Metabolic effects include reduced blood cholesterol, protein synthesis, and sodium and water retention.
Restoration of hormonal balance in various deficiency states.
Absorption: Well absorbed after oral administration.
Distribution: Widely distributed. Crosses the placenta and enters breast milk.
Metabolism and Excretion: Mostly metabolized by the liver and other tissues. Enterohepatic recirculation occurs, and more absorption may occur from the GI tract.
Time/action profile (estrogenic effects)
Contraindicated in: Thromboembolic disease; Undiagnosed vaginal bleeding; Obstetric: Known to cause fetal harm; Lactation: ↓ quantity and quality of breast milk.
Use Cautiously in: Underlying cardiovascular disease; Severe hepatic or renal disease; May ↑ risk of endometrial carcinoma.
Adverse Reactions/Side Effects(systemic use)
Central nervous system
- headache (most frequent)
- mental depression
Ear, Eye, Nose, Throat
- intolerance to contact lenses (most frequent)
- worsening of myopia or astigmatism
- MI (life-threatening)
- thromboembolism (life-threatening)
- edema (most frequent)
- hypertension (most frequent)
- nausea (most frequent)
- weight changes (most frequent)
- ↑ appetite
- amenorrhea (most frequent)
- breakthrough bleeding (most frequent)
- dysmenorrhea (most frequent)
- cervical erosion
- loss of libido
- vaginal candidiasis men:
- erectile dysfunction (most frequent)
- testicular atrophy (most frequent)
- acne (most frequent)
- oily skin (most frequent)
- gynecomastia (men) (most frequent)
Fluid and Electrolyte
- sodium and water retention
- leg cramps
- breast tenderness (most frequent)
Drug-Drug interactionMay alter requirement for warfarin, oral hypoglycemic agents, or insulins.Barbiturates or rifampin may ↓ effectiveness.Smoking ↑ the risk of adverse cardiovascular reactions.
Route/DosageVasomotor Symptoms of Menopause/Atrophic Vaginitis/Osteoporosis
Oral (Adults) 0.75–6 mg daily or in a cycle.Female Hypogonadism/Ovarian Failure
Oral (Adults) 1.5–9 mg daily or in a cycle.
Availability (generic available)
Tablets: 0.75 mg, 1.5 mg, 3 mg, 6 mg
- Assess BP before and periodically throughout therapy.
- Monitor intake and output ratios and weekly weight. Report significant discrepancies or steady weight gain.
- Menopause: Assess frequency and severity of vasomotor symptoms.
- Lab Test Considerations: May cause increased HDL, phospholipids, and triglycerides, and decreased serum LDL and total cholesterol concentrations.
- May cause increased serum glucose, sodium, cortisol, prolactin, prothrombin, and factor VII, VIII, IX, and X levels. May decrease serum folate, pyridoxine, antithrombin III, and urine pregnanediol concentrations.
- Monitor hepatic function before and periodically throughout therapy.
- May cause false interpretations of thyroid function tests, false increases in norepinephrine platelet-induced aggregability, and false decreases in metyrapone tests.
Potential Nursing DiagnosesSexual dysfunction (Indications)
- Oral: Administer PO doses with or immediately after food to reduce nausea.
- Vaginal: Manufacturer provides applicator with cream. Dose is marked on the applicator. Wash applicator with mild soap and warm water after each use.
- Instruct patient to take oral medication as directed. If a dose is missed, take as soon as remembered as long as it is not just before next dose. Do not double doses.
- Explain medication schedule to women on 21-day cycle followed by 7 days of not taking medication. Encourage patient to take medication at the same time each day.
- If nausea becomes a problem, advise patient that eating solid food often provides relief.
- Advise patient to report signs and symptoms of fluid retention (swelling of ankles and feet, weight gain), thromboembolic disorders (pain, swelling, or tenderness in extremities; headache; chest pain; blurred vision), mental depression, hepatic dysfunction (yellowed skin or eyes, pruritus, dark urine, light-colored stools), or abnormal vaginal bleeding to health care professional.
- Instruct patient to stop taking medication and notify health care professional if pregnancy is suspected.
- Caution patient that cigarette smoking during estrogen therapy may increase risk of serious side effects, especially for women over age 35.
- Caution patient to use sunscreen and protective clothing to prevent increased pigmentation.
- Advise patient to notify health care professional of medication regimen before treatment or surgery.
- Advise patient treated for osteoporosis that exercise has been found to arrest and reverse bone loss. The patient should discuss any exercise limitations with health care professional before beginning program.
- Emphasize the importance of routine follow-up physical exams, including BP; breast, abdomen, and pelvic examinations; Papanicolaou smears every 6–12 mo; and mammogram every 12 mo or as directed. Health care professional will evaluate possibility of discontinuing medication every 3–6 mo. If on continuous (not cyclical) therapy or without concurrent progestins, endometrial biopsy may be recommended, if uterus is intact.
- Vaginal: Instruct patient in the correct use of applicator. Patient should remain recumbent for at least 30 min after administration. May use sanitary napkin to protect clothing, but do not use tampon. If a dose is missed, do not use the missed dose, but return to regular dosing schedule.
- Resolution of menopausal vasomotor symptoms.
- Decreased vaginal and vulvar itching, inflammation, or dryness associated with menopause.
- Normalization of estrogen levels in patients with ovariectomy or hypogonadism.
- Prevention of osteoporosis.
A trademark for a drug containing estropipate.
a trademark for an estrogen (estropipate).